Cover Image
市場調查報告書

美國女性的健康:女性的尿失禁治療市場

Women's Health: U.S. Markets for Female Urinary Incontinence Therapies

出版商 Medtech Insight 商品編碼 297207
出版日期 內容資訊 英文 191 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
美國女性的健康:女性的尿失禁治療市場 Women's Health: U.S. Markets for Female Urinary Incontinence Therapies
出版日期: 2014年02月01日 內容資訊: 英文 191 Pages
簡介

美國尿失禁的罹患率變得非常高。National Association for Continence (NAFC)的保守估計,推算美國成人有2,500萬人有慢性、一時性的尿失禁(UI)。根據NAFC,尿失禁患者推定75-80%由女性構成,900萬-1300萬人罹患嚴重的症狀。再加上,美國推測可能有330萬個女性罹患導致UI的骨盆器官脫垂(POP),還有1800萬人罹患大便失禁。2012年的美國女性UI治療市場總額,約12億5540萬美金。該市場額預測今後以年複合成長率6.6%擴大,2017年達到17億2720萬美元。

本報告提供美國的女性的尿失禁治療市場相關調查、尿失禁臨床概要、各市場區隔的主要產品、市場分析,及主要企業簡介等,為您概述為以下內容。

摘要整理

第1章 尿失禁臨床概要

  • 泌尿器官系統的生物結構
  • 尿失禁的種類
    • 緊張狀態性尿失禁
    • 膀胱過動症、急性尿失禁
  • 治療

第2章 膀胱過動症的藥物療法

  • 主要產品
  • 市場分析

第3章 注射用尿道膨脹劑

  • 主要產品
  • 市場分析

第4章 尿吊帶設備

  • 主要產品
  • 尿吊帶設備相關的訴訟
  • 市場分析

第5章 薦椎神經刺激劑

  • 主要產品

第6章 非外科的失禁治療

  • 主要產品

第7章 企業簡介

  • Actavis PLC
  • Boston Scientific Corporation
  • Endo Health Solutions, Inc.
  • Johnson & Johnson
  • Medtronic, Inc.
  • Merck & Company, Inc.
  • Uroplasty, Inc.

附錄:企業清單

目錄
Product Code: A472

Incontinence may be defined as the involuntary loss of bladder or bowel control. In the United States (U.S.), urinary incontinence (UI) is highly prevalent. According to the National Association for Continence (NAFC), the condition affects more than 200 million people worldwide, with a conservative estimate of 25 million adults in the U.S. experiencing chronic or transient UI. The NAFC estimates that 75% to 80% of the UI population comprises women, with 9 million to 13 million suffering severe symptoms. Additionally, an estimated 3.3 million women in the U.S. have pelvic organ prolapse (POP), a condition that may result in UI, and an estimated 18.0 million people suffer from fecal incontinence. Despite the high prevalence, urinary incontinence remains vastly undertreated, with an estimated two-thirds of those with the condition forgoing treatment and less than one-half consulting a physician.

This report focuses on minimally invasive therapy systems and medications designed for the treatment of female UI, including OAB pharmaceutical or drug treatments, injectable urethral bulking agents, and urethral sling systems, of which the OAB drug treatments market contributes the vast majority of revenues.

In 2012, the value of the U.S. female UI therapies market (as defined by the scope of this report) totaled approximately $1,255.4 million. The majority of sales were derived from OAB drug revenues due to a large population base, wide availability of prescription and OTC products, and ease of use. Over the forecast period covered by this report, total sales in this market are expected to increase at a compound annual rate of 6.6%, reaching an estimated $1,727.2 million in the year 2017.

This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. female urinary incontinence therapies market. Covered topics in this report include an overview of female urinary incontinence and core therapies, including drug treatments for OAB; injectable urethral bulking agents; urethral sling systems; sacral nerve stimulation, and emerging drugs and technologies.

Table of Contents

EXECUTIVE SUMMARY

  • i. Stress Urinary Incontinence
  • ii. Overactive Bladder and Urge Incontinence
  • iii. Treatment
    • a. Drug Therapy
    • b. Botulinum Toxin
    • c. Bulking Agents
    • d. Implantable Neurostimulation
    • e. Percutaneous Tibial Nerve Stimulation
    • f. Urethral Slings
    • g. Invasive Surgical Options
  • iv. Market Analysis
    • a. Combined Market Forecast
    • b. Overactive Bladder Drug Treatment Market Forecast
    • c. Injectable Urethral Bulking Agents Market Forecast
    • d. Urethral Sling Systems Market Forecast
  • v. Methodology
  • Exhibit ES-1: Female Urinary Incontinence Therapies, Combined Market Forecast, 2012-2017

1. CLINICAL OVERVIEW OF URINARY INCONTINENCE

  • 1.1. Anatomy of the Urinary System
  • 1.2. Types of Urinary Incontinence
    • 1.2.1. Stress Urinary Incontinence
      • 1.2.1.1. Causes
    • 1.2.2. Overactive Bladder and Urge Incontinence
      • 1.2.2.1. Causes
  • 1.3. Treatment
    • 1.3.1. Prescription Drug Therapy
    • 1.3.2. Botulinum Toxin
    • 1.3.3. Bulking Agents
    • 1.3.4. Sacral Nerve Stimulation
      • 1.3.4.1. Implantable Neurostimulation
      • 1.3.4.2. Percutaneous Tibial Nerve Stimulation
    • 1.3.5. Urethral Slings
    • 1.3.6. Surgical Options
  • Exhibit 1-1: Urinary Voiding and Afferent Signaling
  • Exhibit 1-2: Sacral Neuromodulation with an Implanted Electrical Stimulator

2. DRUG TREATMENT FOR OVERACTIVE BLADDER

  • 2.1. Selected Products
    • 2.1.1. Actavis
    • 2.1.2. Allergan
    • 2.1.3. Astellas Pharma
    • 2.1.4. Janssen Pharmaceuticals/Johnson & Johnson
    • 2.1.5. Merck
    • 2.1.6. Pfizer
    • 2.1.7. Medications Under Development
      • 2.1.7.1. Addex Therapeutics
      • 2.1.7.2. Allergan
      • 2.1.7.3. AltheRx Pharmaceuticals
      • 2.1.7.4. Ario Pharma/Seroba Kernel
      • 2.1.7.5. Astellas Pharma
      • 2.1.7.6. Dainippon Sumitomo Pharma with Nippon Shinyaku
      • 2.1.7.7. Ion Channel Innovations
      • 2.1.7.8. Kissei Pharmaceutical with Kyorin Pharmaceutical/Kyorin Holdings
      • 2.1.7.9. Lipella Pharmaceuticals
      • 2.1.7.10. Merck
      • 2.1.7.11. Motif BioSciences
      • 2.1.7.12. Plethora Solutions
      • 2.1.7.13. Recordati
      • 2.1.7.14. Targacept
      • 2.1.7.15. Teva Pharmaceuticals/Teva Pharmaceutical Industries
      • 2.1.7.16. TheraVida
  • 2.2. Market Analysis
    • 2.2.1. Market Forecast
    • 2.2.2. Competitive Analysis
  • Exhibit 2-1: 2014, Selected Overactive Bladder Medications
  • Exhibit 2-2: 2014, Selected Overactive Bladder Medications Under Development
  • Exhibit 2-3: Gelnique Application and Reductions in Urinary Incontinence Episodes versus Placebo
  • Exhibit 2-4: Application of the Oxytrol for Women Patch
  • Exhibit 2-5: Reduction in Daily Urinary Incontinence with the Use of Oxybutynin
  • Exhibit 2-6: Overactive Bladder and the Function of Toviaz and Behavioral Therapy
  • Exhibit 2-7: Empty Liposomes and Chemical Irritation
  • Exhibit 2-8: Overactive Bladder Drug Treatment, Market Forecast, 2012-2017
  • Exhibit 2-9: 2012, Market for Overactive Bladder Drug Treatment, Share by Supplier

3. INJECTABLE URETHRAL BULKING AGENTS

  • 3.1. Selected Products
    • 3.1.1. Boston Scientific
    • 3.1.2. Coloplast
    • 3.1.3. Uroplasty
    • 3.1.4. Others
      • 3.1.4.1. Speciality European Pharma
  • 3.2. Market Analysis
    • 3.2.1. Procedure Volumes
    • 3.2.2. Market Forecast
    • 3.2.3. Competitive Analysis
  • Exhibit 3-1: The Coaptite Injectable Implant Procedure
  • Exhibit 3-2: The Macroplastique Injectable Bulking Agent
  • Exhibit 3-3: Macroplastique Treatment, Key Efficacy Results at 12 Months
  • Exhibit 3-4: Macroplastique Treatment, Key Adverse Events
  • Exhibit 3-5: The Bulkamid Urethral Bulking System and Injection Technique
  • Exhibit 3-6: Injectable Urethral Bulking Therapy, Procedure Volumes Forecast, 2012-2017
  • Exhibit 3-7: Injectable Urethral Bulking Agents, Market Forecast, 2012-2017
  • Exhibit 3-8: 2012, Injectable Urethral Bulking Agents Market, Share by Supplier

4. URETHRAL SLING SYSTEMS

  • 4.1. Selected Products
    • 4.1.1. American Medical Systems/Endo Health Solutions
    • 4.1.2. Bard Medical/C.R. Bard
    • 4.1.3. Boston Scientific
    • 4.1.4. Caldera Medical
    • 4.1.5. Coloplast
    • 4.1.6. Cook Medical/Cook Group
    • 4.1.7. Ethicon/Johnson. Johnson
  • 4.2. Lawsuits Related to Urethral Sling Systems
    • 4.2.1. American Medical Systems/Endo Health Solutions
    • 4.2.2. Boston Scientific
    • 4.2.3. Ethicon/Johnson. Johnson
  • 4.3. Market Analysis
    • 4.3.1. Procedure Volumes
    • 4.3.2. Market Forecast
    • 4.2.3. Competitive Analysis
  • Exhibit 4-1: 2014, Selected Urethral Sling Systems
  • Exhibit 4-2: The MiniArc Precise Sling System
  • Exhibit 4-3: The MiniArc Single-Incision Sling
  • Exhibit 4-4: The MiniArc Pro Sling System
  • Exhibit 4-5: The Monarc Subfascial Hammock
  • Exhibit 4-6: Suprapubic and Transobturator Approaches to Mid-Urethral Sling Placement Using the BioArc SP and BioArc TO Sling Systems
  • Exhibit 4-7: The 12-Step Mid-Urethral Sling Implant Procedure Using the BioArc SP Sling System
  • Exhibit 4-8: The In-Fast Ultra Transvaginal Sling
  • Exhibit 4-9: The Ajust Adjustable Single-Incision Sling
  • Exhibit 4-10: The Align Urethral Support System
  • Exhibit 4-11: The PelviLace Biourethral Support System
  • Exhibit 4-12: Components of the Advantage Transvaginal Mid-Urethral Sling System
  • Exhibit 4-13: Steps in Mid-Urethral Sling Placement Using the Advantage Sling System
  • Exhibit 4-14: The Desara Sling System
  • Exhibit 4-15: Comparison of the Desara Sling System's Mesh with Other Slings
  • Exhibit 4-16: The Aris Transobturator Sling System
  • Exhibit 4-17: The Biodesign Tension-Free Urethral Sling
  • Exhibit 4-18: The TVT Abbrevo Tension-Free Sling System
  • Exhibit 4-19: Safety Advantages of Using the TVT Abbrevo Tension-Free Sling System
  • Exhibit 4-20: Comparable Clinical Improvement at 36 months, Modified TVT Obturator System versus the Original TVT Obturator System
  • Exhibit 4-21: TVT Tension-Free Support and TVT Exact Sling Systems, Comparative Perforation and Voiding Dysfunction Rates
  • Exhibit 4-22: Urethral Sling Placement, Procedure Volumes Forecast, 2012-2017
  • Exhibit 4-23: Urethral Sling Systems, Market Forecast, 2012-2017
  • Exhibit 4-24: 2012, Urethral Sling Systems Market, Share by Supplier

5. SACRAL NERVE STIMULATION

  • 5.1. Selected Products
    • 5.1.1. Medtronic
    • 5.1.2. Uroplasty
      • 5.1.2.1. Urgent PC Revenues
  • Exhibit 5-1: InterStim Device Implantation
  • Exhibit 5-2: The InterStim Therapy System
  • Exhibit 5-3: InterStim Therapy, 12-Month and 5-Year Sustained Clinical Efficacy
  • Exhibit 5-4: The Sacral Plexus
  • Exhibit 5-5: The Urgent PC Neuromodulation System
  • Exhibit 5-6: Percutaneous Tibial Nerve Stimulation Using the Urgent PC Neuromodulation System, Meta-Analysis Summary

6. NONSURGICAL INCONTINENCE THERAPIES

  • 6.1. Selected Products
    • 6.1.1. Floelle
    • 6.1.2. NexHand
    • 6.1.3. Solace Therapeutics
    • 6.1.4. Verathon/Roper Industries
  • Exhibit 6-1: The Lyrette Transurethral SUI System and Benefits of Treatment
  • Exhibit 6-2: The Lyrette Procedure and Mechanism of Action

7. COMPANY PROFILES

  • 7.1. Actavis PLC
  • 7.2. Boston Scientific Corporation
  • 7.3. Endo Health Solutions, Inc.
  • 7.4. Johnson & Johnson
  • 7.5. Medtronic, Inc.
  • 7.6. Merck & Company, Inc.
  • 7.7. Uroplasty, Inc.

APPENDIX: COMPANY LISTING

Back to Top